• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

FDA Drug Safety Podcast for Healthcare Professionals: Connection problems involving certain needleless pre-filled glass syringes containing adenosine and amiodarone

Listen to this podcast

Welcome, my name is Jennifer Shepherd, a pharmacist in the Division of Drug Information.  On May 6, 2011, the Food and Drug Administration issued a Drug Safety Communication alerting the healthcare community about syringe connection problems when certain needleless glass syringes containing the cardiac drugs adenosine and amiodarone are used with particular types of intravenous access systems. The adenosine and amiodarone needleless pre-filled glass syringes and the IV access systems known to be affected by this announcement are listed in the Drug Safety Communication. 

Adenosine and amiodarone are often used in emergency situations where immediate delivery of the medication is critical. These drugs are administered when a patient has a rapid or irregular heart rhythm in an attempt to return the patient's heart rhythm to normal.   

FDA has received reports that the adenosine and amiodarone pre-filled glass syringes can become clogged and malfunction during the process of connecting them to pin-activated needleless IV access systems.  The incompatibility is not detected until after the syringe is inserted into the pin-activated needleless IV access system. The action of inserting the syringe can cause the pin in the access system to clog or break off in the syringe tip, preventing delivery of the medication. In some cases, the syringe may damage the IV tubing and/or the needleless access system and require reestablishment of IV access. These failures can cause a delay in administration of the medication in emergency situations, and could potentially result in serious harm to patients.

In November 2010, FDA issued a Letter to Stakeholders, alerting the healthcare community about the possibility of needleless pre-filled glass syringe malfunction. FDA, however, has continued to receive additional reports of adverse events related to syringe clogging and malfunction. 

Because of adverse event reports related to amiodarone in needleless pre-filled glass syringes, Sagent Pharmaceuticals, Inc., the manufacturer of the product, has voluntarily recalled all lots of the product to the user level.  

The manufacturers of currently marketed pre-filled glass syringes containing adenosine have revised the label to include a Caution statement in the Dosage and Administration section to inform healthcare professionals about incompatibility of the syringes with certain needleless IV access systems. A recall of all pre-filled glass syringes containing adenosine is not possible at this time because the current supply of adenosine in vials is not adequate to meet demand.  

FDA is continuing to evaluate this safety issue and is working with the product manufacturers to address the problem. 

At this time, FDA recommends that Healthcare Professionals

  1. Know that adenosine and amiodarone needleless pre-filled glass syringes are incompatible with certain needleless pin-activated IV access systems.
  2. Stock crash carts, ambulances, and emergency rooms with adenosine and amiodarone supplied in vials or pre-filled plastic syringes, if possible. Healthcare professionals should read the label of the pre-filled plastic syringes to ensure they are compatible with the IV access systems.  The use of needleless pre-filled glass syringes in emergency situations should be avoided, if possible.  
  3. Report adverse events or problems experienced with the use of needleless pre-filled glass syringes to the FDA MedWatch program at www.fda.gov/medwatch.

Thank you for listening. The FDA is committed to keeping healthcare professionals informed of the latest safety information.  Please read the Drug Safety Communication for a list of affected adenosine and amiodarone products, the data summary and photos detailing this communication.  A link to this DSC can be found at www.fda.gov/Drugs/DrugSafety.   If you have drug questions, you can reach us at druginfo@fda.hhs.gov.

 

Contact FDA

Toll Free
(855) 543-3784, or
(301) 796-3400
Human Drug Information

Division of Drug Information (CDER)

Office of Communications

Feedback Form

10001 New Hampshire Avenue

Hillandale Building, 4th Floor

Silver Spring, MD 20993